The first thing most of my patients notice on a GLP-1 medication isn’t the weight loss.
Dr. Jeff Kindred, DOIt’s the quiet.
The constant mental negotiation with food — the afternoon cravings, the late-night pull toward the kitchen, the feeling that you’re always one bad day away from derailing yourself — just stops. Clinicians call it “food noise,” and for people who’ve lived with it their whole lives, its absence can feel almost disorienting at first.
That quiet is what makes these medications different. It’s not willpower. It’s biology. And when the noise stops, something else starts: the weight begins to come off, movement feels easier, and for a lot of people, exercise becomes something they actually want to do rather than something they dread. That momentum is real — and it can be genuinely life-changing.
But somewhere between the before-and-after photos and the dinner party conversations, a concern started circulating: these drugs make you lose muscle.
It’s a fair concern. And it deserves a real answer — not reassurance, not dismissal, but actual data.
What GLP-1 Medications Actually Do
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and others — work by mimicking hormones that regulate appetite, slow gastric emptying, and improve insulin signaling. The result is reduced caloric intake, often dramatically so, without the constant hunger that makes traditional dieting so difficult to sustain.
They are among the most effective weight loss tools we’ve ever had. Semaglutide 2.4 mg weekly produces roughly 15% total body weight loss. Tirzepatide at its highest dose produces 20–21%. Those are numbers we previously only saw with bariatric surgery.
Which brings us directly to the muscle question.
The Concern About Muscle Loss — And What the Research Actually Shows
When you lose a significant amount of weight by any method, you lose both fat mass and lean mass. That’s not a GLP-1 problem — it’s a basic physiology problem. The question is whether GLP-1 medications make that lean mass loss worse than other approaches.
The evidence says no.
A comprehensive meta-analysis found that GLP-1 receptor agonists reduced lean mass by approximately 0.86 kg — representing about 25% of total weight lost — while fat mass accounted for the large majority of weight reduction. [1] Critically, the relativelean mass percentage remained unchanged. Meaning: the proportion of lean mass to total body weight was preserved, even as total weight came down.
A joint advisory from multiple major medical societies put it plainly: “These reductions in fat mass, lean body mass, and muscle mass correlate with the degree of body weight reduction and are similar to those documented with other obesity therapies that achieve large weight reductions, such as bariatric surgery and very low-calorie restricted diets.” [2]
In other words: GLP-1 medications are not uniquely bad for muscle. They perform comparably to the most effective weight loss interventions we have — including surgery.
Why the Concern Persists — And Why It’s Not Entirely Wrong
Here’s where nuance matters.
Because GLP-1 medications produce such substantial total weight loss, the absolute number on muscle can look alarming. If you lose 40 pounds, even a proportionally normal lean mass reduction represents several pounds of muscle. That’s real, and it matters — especially for older patients where muscle preservation is directly tied to longevity, function, and fall prevention.
This isn’t a reason to avoid GLP-1 medications. It’s a reason to manage them properly.
There’s also evidence that GLP-1 medications may actually improve muscle quality — specifically by reducing intramuscular fat infiltration, which is a marker of muscle function that the scale and even DEXA can’t fully capture. [3] Fat-free mass to fat mass ratio improves substantially with treatment, meaning the overall composition picture is favorable even when absolute lean mass numbers decrease.
How to Protect Your Muscle While on a GLP-1
This is where clinical management makes a real difference. The research is clear on two levers:
Protein intake. Research on caloric restriction and lean mass preservation consistently points toward targeting 1.2–1.6 grams of protein per kilogram of body weight daily to meaningfully reduce muscle loss. [4] That range is well-supported in the general weight loss literature and is reasonably applied to GLP-1 therapy — though GLP-1-specific protein intervention trials are still emerging. What we do know is that the RDA of 0.8 g/kg is almost certainly not enough when you’re losing significant weight. This is harder than it sounds when appetite is suppressed — which is exactly why it requires intentional attention, not just a general recommendation to “eat more protein.”
Resistance training. When GLP-1 therapy is combined with structured resistance exercise, lean mass can be preserved or even increased while fat loss continues. [5] This is one of the most important findings in the literature — and one of the most underutilized in practice. Most patients are handed a prescription and told to exercise. That’s not the same as having an actual plan.
And here’s where the food noise piece comes back in. Because one of the things I see consistently is this: once the medication quiets the appetite and the weight starts moving, people feel better in their bodies. Their joints hurt less. Walking up stairs isn’t exhausting. Exercise becomes accessible in a way it wasn’t before. That’s not a side effect — that’s the point. Movement that builds muscle becomes achievable, often for the first time in years.
What Monitoring Actually Looks Like
At Hi, Finch Health, anyone on a GLP-1 medication gets more than a prescription. They get a framework:
DEXA scans track body composition over time — not just weight on a scale, but the actual ratio of fat to lean mass. We’ve written about why DEXA is one of the most important tests most people aren’t getting. On a GLP-1, it becomes even more essential. A personalized exercise prescription — built around resistance training, not just cardio — is part of the plan from day one. Protein targets are set based on body weight, not generic advice. And dosing is adjusted based on how the patient is actually responding, not just a standard titration schedule.
This is the difference between taking a medication and using it well.
It’s also worth noting: many people are currently paying $150–$300 per month to telehealth platforms simply to have their GLP-1 prescription written and renewed — with little else included. At Hi, Finch Health, GLP-1 management is part of your membership. The monitoring, the body composition tracking, the exercise prescription, the protein targets, the physician relationship — all of it. No separate subscription. No extra fees.
The Bottom Line
GLP-1 medications are not perfect. No tool is. But the muscle loss concern, taken in isolation and without context, has scared some people away from an intervention that could genuinely change their health trajectory.
The data shows that lean mass loss with GLP-1 therapy is proportionally similar to other effective weight loss methods. It can be meaningfully reduced with the right protein intake and resistance training. And the downstream effects — reduced food noise, sustainable weight loss, improved mobility, and the motivation to move — often create the conditions for building the healthiest, most functional body a patient has had in years.
That’s worth taking seriously. And it’s worth doing right.
If you’re considering a GLP-1 medication and want to understand how it fits into a broader health strategy, reach out to Hi, Finch Health. This is exactly the kind of decision that benefits from a physician who has the time to think through the whole picture with you.
References
- “Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.” JAMA Netw Open.2026;9(1). JAMA Network Open
- Mozaffarian D, Agarwal M, et al. “Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.” Am J Clin Nutr. 2025. PubMed Central
- Perna S, et al. “Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.” Metabolism. 2025. PubMed
- Cava E, et al. “Preserving Healthy Muscle during Weight Loss.” Advances in Nutrition. 2017;8(3):511–519. PubMed
- Lundgren JR, et al. “Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.” NEJM.2021;384:1719–1730. PubMed